• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

停用皮质类固醇后持续存在的躁狂症。

Persistent mania following cessation of corticosteroids.

作者信息

Roxanas Milton G

机构信息

Asssociate Professor of Psychiatry, Sydney Adventist Medical School, University of Sydney, Sydney, NSW, Australia.

出版信息

Australas Psychiatry. 2018 Oct;26(5):520-523. doi: 10.1177/1039856218758566. Epub 2018 Feb 15.

DOI:10.1177/1039856218758566
PMID:29446641
Abstract

OBJECTIVES

The aims of this study are to describe two patients whose manic symptoms persisted for several months after the cessation of corticosteroids, to review the literature and to suggest treatment.

METHODS

The presentation of two elderly patients with persistent manic symptoms following cessation of corticosteroids several months previously afforded the author the opportunity to examine them carefully, investigate and treat them.

RESULTS

The patients were investigated to rule out other causes and were treated with sodium valproate and quetiapine (in the second patient). When well, the medications were slowly decreased and stopped. Both patients were well at one-year follow-up.

CONCLUSIONS

Manic symptoms may persist for many months after stopping corticosteroids and active treatment is needed to control them.

摘要

目的

本研究旨在描述两名患者,其躁狂症状在停用皮质类固醇激素后持续数月,回顾相关文献并提出治疗建议。

方法

两名老年患者在数月前停用皮质类固醇激素后出现持续躁狂症状,作者有机会对他们进行仔细检查、调查和治疗。

结果

对患者进行检查以排除其他病因,给予丙戊酸钠治疗(第二名患者还使用了喹硫平)。病情好转后,逐渐减少并停用药物。两名患者在一年随访时情况良好。

结论

停用皮质类固醇激素后,躁狂症状可能持续数月,需要积极治疗以控制症状。

相似文献

1
Persistent mania following cessation of corticosteroids.停用皮质类固醇后持续存在的躁狂症。
Australas Psychiatry. 2018 Oct;26(5):520-523. doi: 10.1177/1039856218758566. Epub 2018 Feb 15.
2
Expect psychiatric side effects from corticosteroid use in the elderly.
Geriatrics. 2008 Jan;63(1):15-8.
3
Rapid reversal of corticosteroid-induced mania with sodium valproate: a case series of 20 patients.丙戊酸钠快速逆转皮质类固醇诱导的躁狂症:20 例病例系列。
Psychosomatics. 2012 Nov-Dec;53(6):575-81. doi: 10.1016/j.psym.2012.06.006.
4
Sustained corticosteroid- induced mania and psychosis despite cessation: A case study and brief literature review.尽管停用仍持续存在的皮质类固醇诱发的躁狂和精神病:一项病例研究及简要文献综述
Int J Psychiatry Med. 2015;50(4):398-404. doi: 10.1177/0091217415612735.
5
Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.喹硫平治疗急性双相躁狂症:对广泛症状的疗效。
J Affect Disord. 2007;100 Suppl 1:S5-14. doi: 10.1016/j.jad.2007.02.007. Epub 2007 Mar 27.
6
Corticosteroids and mania: A systematic review.皮质类固醇与躁狂症:一项系统综述。
World J Biol Psychiatry. 2024 Mar;25(3):161-174. doi: 10.1080/15622975.2024.2312572. Epub 2024 Mar 13.
7
Bipolar disorder and Susac syndrome: a case report.
Int Clin Psychopharmacol. 2021 Nov 1;36(6):305-309. doi: 10.1097/YIC.0000000000000375.
8
Gabapentin in geriatric mania.加巴喷丁用于老年躁狂症。
J Geriatr Psychiatry Neurol. 2003 Jun;16(2):117-20. doi: 10.1177/0891988703016002010.
9
Drug-induced mania.
Drug Saf. 1995 Feb;12(2):146-53. doi: 10.2165/00002018-199512020-00007.
10
Treating mixed mania/hypomania: a review and synthesis of the evidence.治疗混合性躁狂/轻躁狂:证据综述与整合
CNS Spectr. 2017 Apr;22(2):177-185. doi: 10.1017/S1092852916000845. Epub 2016 Dec 22.

引用本文的文献

1
Corticosteroid-induced manic and/or psychotic symptoms: a systematic review.皮质类固醇诱发的躁狂和/或精神病性症状:一项系统综述
Front Pharmacol. 2025 Jul 22;16:1628765. doi: 10.3389/fphar.2025.1628765. eCollection 2025.
2
Is SARS-CoV-2 a Risk Factor of Bipolar Disorder?-A Narrative Review.严重急性呼吸综合征冠状病毒2是双相情感障碍的危险因素吗?——一项叙述性综述。
J Clin Med. 2022 Oct 14;11(20):6060. doi: 10.3390/jcm11206060.
3
Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with Glucocorticoids.接受糖皮质激素治疗的老年人的行为、精神和认知不良事件。
Medicines (Basel). 2018 Aug 1;5(3):82. doi: 10.3390/medicines5030082.